Veradermics' VDPHL01 Meets All Endpoints in Phase 3 Study '304' Part A

Veradermics, Incorporated's lead candidate VDPHL01 met all primary and secondary endpoints in the six-month, placebo-controlled Part A of Phase 3 Study '304,' involving men with mild-to-moderate pattern hair loss. Study '304' enrolled 536 men. Pattern hair loss is also known as androgenetic alopecia. The result covers Part A of the trial, which also includes a longer extension. The finding gives Veradermics a positive late-stage result for its lead candidate. It applies to the six-month comparison with placebo, rather than the study's longer extension. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.